William T Abraham

Summary

Affiliation: The Ohio State University
Country: USA

Publications

  1. ncbi Cardiac resynchronization therapy for heart failure: biventricular pacing and beyond
    William T Abraham
    Division of Cardiovascular Medicine, Gill Heart Institute, Heart Failure and Cardiac Transplantation Program, University of Kentucky College of Medicine, Lexington, Kentucky 49536, USA
    Curr Opin Cardiol 17:346-52. 2002
  2. ncbi Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure
    William T Abraham
    Ohio State University Heart Center, Division of Cardiovascular Medicine, 473 W 12th Ave, Room 110P DHLRI, Columbus, OH 43210 1252
    Circulation 110:2864-8. 2004
  3. ncbi Electrophysiological aids in congestive heart failure: supporting and synchronizing systole
    William T Abraham
    Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH 43210 1252, USA
    Med Clin North Am 87:509-21. 2003
  4. ncbi Cardiac resynchronization therapy for heart failure
    William T Abraham
    Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, USA
    Circulation 108:2596-603. 2003
  5. ncbi Angiotensin-converting enzyme DD genotype in patients with primary pulmonary hypertension: increased frequency and association with preserved haemodynamics
    William T Abraham
    Department of Medicine, University of Colorado, School of Medicine, Denver, USA
    J Renin Angiotensin Aldosterone Syst 4:27-30. 2003
  6. ncbi Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients
    William T Abraham
    The Ohio State University Heart Center, Division of Cardiovascular Medicine, Columbus, Ohio 43210 1252, USA
    J Am Coll Cardiol 47:1615-21. 2006
  7. ncbi In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE)
    William T Abraham
    Division of Cardiovascular Medicine, The Ohio State University, Columbus, Ohio, USA
    J Am Coll Cardiol 46:57-64. 2005
  8. ncbi Cardiac resynchronization therapy for the management of chronic heart failure
    William T Abraham
    Department of Internal Medicine, Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, Ohio State University, Columbus, OH, USA
    Am Heart Hosp J 1:55-61. 2003
  9. ncbi Switching between beta blockers in heart failure patients: rationale and practical considerations
    William T Abraham
    Davis Heart and Lung Research Institute, The Ohio State University Heart Center, Columbus, OH 43210 1252, USA
    Congest Heart Fail 9:271-8. 2003
  10. ncbi Cardiac resynchronization therapy
    William T Abraham
    Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH 43210 1252, USA
    Prog Cardiovasc Dis 48:232-8. 2006

Research Grants

Detail Information

Publications118 found, 100 shown here

  1. ncbi Cardiac resynchronization therapy for heart failure: biventricular pacing and beyond
    William T Abraham
    Division of Cardiovascular Medicine, Gill Heart Institute, Heart Failure and Cardiac Transplantation Program, University of Kentucky College of Medicine, Lexington, Kentucky 49536, USA
    Curr Opin Cardiol 17:346-52. 2002
    ..In addition, the results of recently completed clinical trials, as well as the status of ongoing clinical trials, are reviewed...
  2. ncbi Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure
    William T Abraham
    Ohio State University Heart Center, Division of Cardiovascular Medicine, 473 W 12th Ave, Room 110P DHLRI, Columbus, OH 43210 1252
    Circulation 110:2864-8. 2004
    ..The effects of cardiac resynchronization therapy (CRT) in patients with mildly symptomatic heart failure have not been fully elucidated...
  3. ncbi Electrophysiological aids in congestive heart failure: supporting and synchronizing systole
    William T Abraham
    Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH 43210 1252, USA
    Med Clin North Am 87:509-21. 2003
    ..Ongoing and future clinical trials should help to further validate the role of cardiac resynchronization in the treatment of patients with systolic HF...
  4. ncbi Cardiac resynchronization therapy for heart failure
    William T Abraham
    Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, USA
    Circulation 108:2596-603. 2003
  5. ncbi Angiotensin-converting enzyme DD genotype in patients with primary pulmonary hypertension: increased frequency and association with preserved haemodynamics
    William T Abraham
    Department of Medicine, University of Colorado, School of Medicine, Denver, USA
    J Renin Angiotensin Aldosterone Syst 4:27-30. 2003
    ....
  6. ncbi Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients
    William T Abraham
    The Ohio State University Heart Center, Division of Cardiovascular Medicine, Columbus, Ohio 43210 1252, USA
    J Am Coll Cardiol 47:1615-21. 2006
    ..The purpose of this study was to examine the renal effects of a V2 receptor arginine vasopressin (AVP) antagonist in heart failure...
  7. ncbi In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE)
    William T Abraham
    Division of Cardiovascular Medicine, The Ohio State University, Columbus, Ohio, USA
    J Am Coll Cardiol 46:57-64. 2005
    ..We sought to compare the in-hospital mortality of patients with acute decompensated heart failure (ADHF) who were receiving parenteral treatment with one of four intravenous vasoactive medications...
  8. ncbi Cardiac resynchronization therapy for the management of chronic heart failure
    William T Abraham
    Department of Internal Medicine, Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, Ohio State University, Columbus, OH, USA
    Am Heart Hosp J 1:55-61. 2003
    ..Thus, cardiac resynchronization therapy should be routinely considered in eligible NYHA class III and IV heart failure patients with ventricular dyssynchrony...
  9. ncbi Switching between beta blockers in heart failure patients: rationale and practical considerations
    William T Abraham
    Davis Heart and Lung Research Institute, The Ohio State University Heart Center, Columbus, OH 43210 1252, USA
    Congest Heart Fail 9:271-8. 2003
    ..The optimal selection and use of adrenergic-blocking agents in the cardiovascular continuum will assist in providing improved management while minimizing safety and tolerability concerns...
  10. ncbi Cardiac resynchronization therapy
    William T Abraham
    Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH 43210 1252, USA
    Prog Cardiovasc Dis 48:232-8. 2006
    ..Cardiac resynchronization therapy has been shown to significantly improve LV structure and function, New York Heart Association functional class, exercise tolerance, quality of life, and morbidity and mortality...
  11. ncbi Clinical and hemodynamic effects of nesiritide (B-type natriuretic peptide) in patients with decompensated heart failure receiving beta blockers
    William T Abraham
    Division of Cardiovascular Medicine, The Ohio State University, Columbus, OH 43210 1252, USA
    Congest Heart Fail 11:59-64. 2005
    ..Thus, the clinical and hemodynamic benefits and safety of nesiritide are preserved in decompensated congestive heart failure patients receiving chronic beta blockade...
  12. doi Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure)
    Gregg C Fonarow
    Department of Medicine, UCLA Medical Center, Los Angeles, CA, USA
    Am J Cardiol 102:1524-9. 2008
    ..In the first 60 to 90 days after hospital discharge, little up-titration in beta-blocker dosing occurs. Further efforts are needed to help understand and overcome this beta-blocker titration gap...
  13. ncbi Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry
    Gregg C Fonarow
    Ahmanson UCLA Cardiomyopathy Center, Department of Medicine, UCLA Medical Center, Los Angeles, California 90095 1679, USA
    J Am Coll Cardiol 50:768-77. 2007
    ..We sought to evaluate the characteristics, treatments, and outcomes of patients with preserved and reduced systolic function heart failure (HF)...
  14. doi Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF
    Gregg C Fonarow
    Department of Medicine, UCLA University of California, Los Angeles Medical Center, Los Angeles, CA 90095 1679, USA
    Arch Intern Med 168:847-54. 2008
    ..This study evaluated the association between precipitating factors identified at the time of HF hospital admission and subsequent clinical outcomes...
  15. doi Postoperative hyponatremia predicts an increase in mortality and in-hospital complications after cardiac surgery
    Juan A Crestanello
    Division of Cardiac Surgery, Wexner Medical Center, The Ohio State University, Columbus, OH, USA
    J Am Coll Surg 216:1135-43, 1143.e1. 2013
    ..The association between postoperative hyponatremia (Na < 135 mEq/L) and outcomes after cardiac surgery has not been established. We studied the prevalence of postoperative hyponatremia and its effects on outcomes after cardiac surgery...
  16. ncbi Beta-blocker dosing in community-based treatment of heart failure
    Michael B Fowler
    Division of Cardiovascular Medicine, Stanford University Medical Center, Palo Alto, CA, USA
    Am Heart J 153:1029-36. 2007
    ..Community patients with heart failure (HF) are older, less often treated by HF specialists, and have more comorbidity than those in randomized clinical trials. These differences might affect beta-blocker prescribing in HF...
  17. doi Randomized controlled trial of ventricular elastic support therapy in the treatment of symptomatic heart failure: rationale and design
    William T Abraham
    The Ohio State University Heart Center, Columbus, OH 43210 1252, USA
    Am Heart J 164:638-45. 2012
    ..The Prospective Evaluation of Elastic Restraint to LESSen the effects of Heart Failure (PEERLESS-HF) trial was designed to further evaluate the safety and efficacy of one such device, the HeartNet (Paracor Medical, Sunnyvale, CA)...
  18. doi Does preoperative hyponatremia potentiate the effects of left ventricular dysfunction on mortality after cardiac surgery?
    Juan A Crestanello
    Division of Cardiac Surgery, The Ohio State University Medical Center, Columbus, Ohio, USA
    J Thorac Cardiovasc Surg 145:1589-94, 1594.e1-2. 2013
    ..Thus, we evaluated the interaction of low left ventricular ejection fraction (<40%) and preoperative hyponatremia (Na <135 mEq/L) with morbidity and mortality after cardiac surgery...
  19. doi Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry)
    James B Young
    Department of Cardiovascular Medicine, Heart Failure Section, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Cardiol 101:223-30. 2008
    ..Lower hemoglobin is associated with higher morbidity and mortality in hospitalized patients with HF...
  20. doi Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF)
    William T Abraham
    Division of Cardiology, The Ohio State University, Columbus, Ohio, USA
    J Am Coll Cardiol 52:347-56. 2008
    ..The aim of this study was to develop a clinical model predictive of in-hospital mortality in a broad hospitalized heart failure (HF) patient population...
  21. doi Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program
    Gregg C Fonarow
    Department of Medicine, University of California Los Angeles Medical Center, Los Angeles, California 90095 1679, USA
    J Am Coll Cardiol 52:190-9. 2008
    ..This study ascertains the relationship between continuation or withdrawal of beta-blocker therapy and clinical outcomes in patients hospitalized with systolic heart failure (HF)...
  22. ncbi Prospective evaluation of beta-blocker use at the time of hospital discharge as a heart failure performance measure: results from OPTIMIZE-HF
    Gregg C Fonarow
    Department of Medicine, University of California Los Angeles Medical Center, Los Angeles, California 90095 1679, USA
    J Card Fail 13:722-31. 2007
    ..The objective of this study was to prospectively evaluate beta-blocker use at hospital discharge as an indicator of quality of care and outcomes in patients with heart failure (HF)...
  23. ncbi Tolerability, safety, and efficacy of beta-blockade in black patients with heart failure in the community setting: insights from a large prospective beta-blocker registry
    William T Abraham
    Division of Cardiovascular Medicine, The Ohio State University School of Medicine, Columbus, OH, USA
    Congest Heart Fail 13:16-21. 2007
    ..9% vs 7.5%, hazard ratio 1.2 vs 1.0, P=.276). Thus carvedilol was similarly effective in blacks and whites with HF in the community setting, consistent with carvedilol clinical trials...
  24. doi Day of admission and clinical outcomes for patients hospitalized for heart failure: findings from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF)
    Gregg C Fonarow
    Department of Medicine, University of California Los Angeles Medical Center, Los Angeles, CA 90095 1679, USA
    Circ Heart Fail 1:50-7. 2008
    ..This study examined the relationship between the day of the week patients are hospitalized for HF and death rate, length of stay (LOS), and rehospitalization rate...
  25. ncbi Continuous autonomic assessment in patients with symptomatic heart failure: prognostic value of heart rate variability measured by an implanted cardiac resynchronization device
    Philip B Adamson
    Department of Medicine, Cardiovascular Disease and Physiology, University of Oklahoma Health Sciences Center, 920 SL Young Blvd, WP3120, Oklahoma City, OK 73104, USA
    Circulation 110:2389-94. 2004
    ..Long-term continuous HRV can be measured from an implantable device, but the clinical value of these measurements is unknown...
  26. ncbi Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF)
    Gregg C Fonarow
    Department of Medicine, University of California Los Angeles Medical Center, 10833 LeConte Ave, Room 47 123 CHS, Los Angeles, CA 90095 1679, USA
    Arch Intern Med 167:1493-502. 2007
    ..We sought to evaluate the effect of a national hospital-based initiative on quality of care in patients hospitalized with HF...
  27. doi Percutaneous left ventricular partitioning in patients with chronic heart failure and a prior anterior myocardial infarction: Results of the PercutAneous Ventricular RestorAtion in Chronic Heart failUre PaTiEnts Trial
    Ernest L Mazzaferri
    Division of Cardiovascular Medicine, The Ohio State University Heart and Vascular Center, 473 West 12th Ave, Columbus, OH 43210 1252, USA
    Am Heart J 163:812-820.e1. 2012
    ..The aim of this study was to assess the feasibility, safety, and preliminary efficacy of a novel percutaneous left ventricular partitioning device (VPD) in patients with chronic heart failure (HF) and a prior anterior myocardial infarction...
  28. doi A smoker's paradox in patients hospitalized for heart failure: findings from OPTIMIZE-HF
    Gregg C Fonarow
    Department of Medicine, UCLA Medical Center, Los Angeles, CA, USA
    Eur Heart J 29:1983-91. 2008
    ..This study aimed to ascertain the relationship between smoking and clinical outcomes in patients hospitalized with heart failure (HF)...
  29. doi The PARACHUTE IV trial design and rationale: percutaneous ventricular restoration using the parachute device in patients with ischemic heart failure and dilated left ventricles
    Marco A Costa
    University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH, USA
    Am Heart J 165:531-6. 2013
    ..These data compare favorably with historical data and support the need of a randomized trial to determine the clinical efficacy of PVR on outcomes for patients with ischemic HF...
  30. ncbi Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial
    Arthur M Feldman
    Department of Medicine, Jefferson Medical College, Philadelphia, PA 19107, USA
    Am Heart J 154:861-9. 2007
    ..v.) inotropic support. Chronic parenteral inotropic therapy in UA-HF is costly and requires an indwelling catheter. An effective and safe oral inotrope would have value...
  31. ncbi Canine nonischemic left ventricular dysfunction: a model of chronic human cardiomyopathy
    Yoshinori Nishijima
    Department of Veterinary Biosciences, The Ohio State University, Columbus, Ohio 43210, USA
    J Card Fail 11:638-44. 2005
    ..The mechanisms of cardiac remodeling during chronic heart failure remain poorly defined. We sought to advance a chronic canine model of nonischemic cardiomyopathy...
  32. ncbi Cardiac resynchronization in chronic heart failure
    William T Abraham
    Division of Cardiovascular Medicine, University of Kentucky College of Medicine, Lexington 40536 0284, USA
    N Engl J Med 346:1845-53. 2002
    ..We conducted a double-blind trial to evaluate this therapeutic approach...
  33. ncbi Effect of treatment with continuous positive airway pressure or oxygen on sleep-disordered breathing in patients with heart failure: results of the Sleep Events, Arrhythmias, and Respiratory Analysis in Chronic Heart Failure (SEARCH) study
    William T Abraham
    The Ohio State University Heart Center, Columbus, OH 43210, USA
    Congest Heart Fail 14:197-201. 2008
    ..5%) experienced a 16.7-events/h mean reduction in AHI. Thus, the Clear Path system appears to be a useful device to monitor response to SDB-directed treatment for apnea in patients with heart failure...
  34. doi Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial
    William T Abraham
    Ohio State University Heart and Vascular Center, Columbus, OH, USA
    Lancet 377:658-66. 2011
    ..Results of previous studies support the hypothesis that implantable haemodynamic monitoring systems might reduce rates of hospitalisation in patients with heart failure. We undertook a single-blind trial to assess this approach...
  35. doi Randomized controlled trial comparing simultaneous versus optimized sequential interventricular stimulation during cardiac resynchronization therapy
    William T Abraham
    The Ohio State University Heart Center, Columbus, OH 43210 1252, USA
    Am Heart J 164:735-41. 2012
    ..This randomized, double-blind, controlled study evaluated whether optimizing the interventricular stimulating interval (V-V) to sequentially activate the ventricles is clinically better than simultaneous V-V stimulation during CRT...
  36. ncbi Carvedilol improves left ventricular function in heart failure patients with idiopathic dilated cardiomyopathy and a wide range of sympathetic nervous system function as measured by iodine 123 metaiodobenzylguanidine
    Myron C Gerson
    Division of Cardiology, Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio 45267, USA
    J Nucl Cardiol 9:608-15. 2002
    ..The goal of this study was to determine the effect of chronic carvedilol treatment in patients with cardiac sympathetic nerve dysfunction of varying severity...
  37. ncbi Predictors of clinical outcomes in patients given carvedilol for heart failure
    Barry Greenberg
    University of California, San Diego, School of Medicine, San Diego, California, USA
    Am J Cardiol 98:1480-4. 2006
    ..In this unselected community population, these historical factors were better predictors of risk than the left ventricular ejection fraction...
  38. doi Cardiac contractility modulation in patients with advanced heart failure
    Rami Kahwash
    Davis Heart and Lung Research Institute, 473 W 12th Ave, Columbus, OH 43210, USA
    Expert Rev Cardiovasc Ther 11:635-45. 2013
    ..The device is currently available for the treatment of heart failure in Europe. Approval in the USA is pending additional testing currently underway using a protocol approved by the US FDA...
  39. doi Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia
    William T Abraham
    Division of Cardiovascular Medicine, Ohio State University, Columbus, Ohio 43210 1252, USA
    Kidney Int 82:1215-22. 2012
    ..2%). Overall, lixivaptan was considered safe and well-tolerated. Thus, oral lixivaptan can be safely initiated in the outpatient setting and effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia...
  40. doi Subgroup analysis of a randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure
    William T Abraham
    Ohio State University Heart Center, Columbus, Ohio, USA
    J Card Fail 17:710-7. 2011
    ..In the present analysis, we sought to identify if there was a subgroup of patients who showed a response to CCM...
  41. pmc A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure
    Stephen B Liggett
    Department of Medicine, University of Maryland, Baltimore, MD 21201, USA
    Proc Natl Acad Sci U S A 103:11288-93. 2006
    ..We conclude that beta(1)AR-389 variation alters signaling in multiple models and affects the beta-blocker therapeutic response in HF and, thus, might be used to individualize treatment of the syndrome...
  42. ncbi Optimization of cardiac resynchronization devices using acoustic cardiography: a comparison to echocardiography
    Ayesha Hasan
    Division of Cardiology, The Ohio State University, Columbus, OH 43210, USA
    Congest Heart Fail 12:25-31. 2006
    ..7%). In addition, it took less time for the acoustic cardiogram to collect sufficient information to make a recommendation, and it was found that the acoustic cardiogram data trend is easier to interpret...
  43. ncbi Predictors of remodeling in the CRT era: influence of mitral regurgitation, BNP, and gender
    Thomas P Cappola
    Division of Cardiovascular Medicine, University of Pennsylvania School of Medicine, Philadelphia, USA
    J Card Fail 12:182-8. 2006
    ..We analyzed quantitative echocardiographic data from a large heart failure cohort receiving medical and cardiac resynchronization therapy (CRT) to determine baseline predictors of progressive left ventricular (LV) enlargement...
  44. ncbi Beyond diuretics: management of volume overload in acute heart failure syndromes
    James A Hill
    Division of Cardiovascular Medicine, University of Florida, Gainesville, Florida, USA
    Am J Med 119:S37-44. 2006
    ....
  45. ncbi Noninvasive calibration of cardiac pressure transducers in patients with heart failure: an aid to implantable hemodynamic monitoring and therapeutic guidance
    Dougal McClean
    Division of Cardiology, Department of Medicine, and the Research Institute at Cedars Sinai Medical Center, Los Angeles, California, USA
    J Card Fail 12:568-76. 2006
    ..Implantable cardiac pressure monitors require assurance of calibration. This study evaluated if airway pressure responses during Valsalva maneuver (VM) can be used for calibrating intracardiac pressure transducers...
  46. ncbi Effect of cardiac resynchronization therapy on myocardial gene expression in patients with nonischemic dilated cardiomyopathy
    Srinivas Iyengar
    Division of Cardiovascular Medicine and the Department of Internal Medicine, The Ohio State University, Columbus, Ohio 43210 1252, USA
    J Card Fail 13:304-11. 2007
    ....
  47. ncbi Cardiac resynchronization therapy improves heart rate variability in patients with symptomatic heart failure
    Philip B Adamson
    Department of Internal Medicine, Cardiovascular Disease Section, University of Oklahoma Health Sciences Center, PO Box 26901, 920 SL Young Boulevard, WP3120, Oklahoma City, Okla 73104, USA
    Circulation 108:266-9. 2003
    ..The present study examined whether an improvement in ventricular performance from resynchronization therapy changes the autonomic control of heart rate...
  48. pmc In-hospital testing for sleep-disordered breathing in hospitalized patients with decompensated heart failure: report of prevalence and patient characteristics
    Rami N Khayat
    Division of Pulmonary Critical Care and Sleep, Ohio State University, Columbus, OH, USA
    J Card Fail 15:739-46. 2009
    ..Sleep-disordered breathing (SDB) is present in more than 50% of ambulatory patients with chronic heart failure. The prevalence and type of SDB in hospitalized patients with acutely decompensated heart failure (ADHF) are not known...
  49. ncbi Biventricular and novel pacing mechanisms in heart failure
    Christina Salazar
    Ohio State University, 473 West 12th Avenue, Columbus, OH 43210, USA
    Curr Heart Fail Rep 6:14-8. 2009
    ..In this article, we review CRT's effects on reverse remodeling in an expanding patient population and as a novel pacing mechanism, its cardiac contractility modulation, and its benefits in patients with heart failure...
  50. ncbi Diuretics for the treatment of acute decompensated heart failure
    Srinivas Iyengar
    Division of Cardiovascular Medicine, The Ohio State University, 473 West 12th Avenue, Rm 110P DHLRI, Columbus, Ohio 43210 1252, USA
    Heart Fail Rev 12:125-30. 2007
    ..Given this reality and until further information is available about the most ideal utilization of these medications, diuretics will continue to represent a double-edged sword for physicians treating this disease process...
  51. ncbi Future therapies for heart failure
    Robin J Trupp
    The Heart and Lung Research Institute, The Ohio State University 473 West 12th Avenue, Columbus, OH 43210, USA
    Crit Care Nurs Clin North Am 15:525-30, x. 2003
    ..This article discusses recently approved drugs and devices and clinical trials that may affect the management of this challenging disease...
  52. doi Nesiritide in acute decompensated heart failure: a pooled analysis of randomized controlled trials
    William T Abraham
    Division of Cardiovascular Medicine, The Ohio State University, Columbus, Ohio, USA
    Clin Cardiol 33:484-9. 2010
    ..This study used relevant data from all RCTs of nesiritide in ADHF completed as of June 2006 to independently estimate the effect of nesiritide on 30- and 180-day mortality...
  53. ncbi Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design
    Gregg C Fonarow
    Department of Medicine, UCLA Medical Center, Los Angeles, Calif, USA
    Am Heart J 148:43-51. 2004
    ..The ultimate aim of this program is to improve the standard of HF care in the hospital and outpatient settings and increase the use of evidence-based therapeutic strategies to save lives...
  54. doi A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: rationale, design, and baseline patient characteristics
    William T Abraham
    The Ohio State University Heart Center, Division of Cardiovascular Medicine, Columbus, OH 43210 1252, USA
    Am Heart J 156:641-648.e1. 2008
    ..Baseline characteristics for patients randomized in this trial are also presented...
  55. ncbi Nesiritide for the treatment of congestive heart failure
    Srinivas Iyengar
    Division of Cardiovascular Medicine, The Ohio State University Heart Center, Columbus, OH 43210 1252, USA
    Expert Opin Pharmacother 5:901-7. 2004
    ..Overall, nesiritide represents an effective and safe therapeutic option for the treatment of decompensated CHF...
  56. doi Safety and accuracy of a wireless pulmonary artery pressure monitoring system in patients with heart failure
    William T Abraham
    The Ohio State University Heart Center, Columbus, USA
    Am Heart J 161:558-66. 2011
    ..The goal of this investigation was to evaluate the safety and technical performance of a novel wireless pulmonary artery pressure monitoring system in 17 patients with symptomatic HF...
  57. ncbi New approaches to monitoring heart failure before symptoms appear
    William T Abraham
    Division of Cardiovascular Medicine, Department of Internal Medicine, Ohio State University College of Medicine, Columbus, Ohio, USA
    Rev Cardiovasc Med 7:S33-41. 2006
    ..IHM systems may extend such monitoring capabilities. Both emerging approaches for monitoring patients with heart failure may alert clinicians (and possibly patients) to impending decompensation before symptoms appear...
  58. doi Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) study
    William T Abraham
    Division of Cardiovascular Medicine, The Ohio State University Heart Center, Columbus, USA
    Clin Transl Sci 3:249-53. 2010
    ..BALANCE seeks to address unmet questions regarding the use of vasopressin antagonists including their effects on cognitive function and clinical outcomes in patients with hyponatremia and worsening heart failure...
  59. doi Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures
    Michael R Zile
    Department of Medicine, Division of Cardiology, Medical University of South Carolina, Charleston, SC 29425, USA
    Circulation 118:1433-41. 2008
    ..The purpose of this study was to use echocardiographic and implantable hemodynamic monitor data to examine the pathophysiology of chronic compensated and acute decompensated HF in SHF versus DHF patients...
  60. doi Pharmacologic therapies across the continuum of left ventricular dysfunction
    William T Abraham
    Division of Cardiovascular Medicine, Ohio State University Medical Center, Columbus, Ohio 43210, USA
    Am J Cardiol 102:21G-28G. 2008
    ..This review illustrates the impact of these therapies on post-MI LVD patients using evidence from multiple clinical trials. In addition, current and emerging treatments for acute decompensated HF will be outlined...
  61. ncbi Mechanisms of disease: beta-adrenergic receptors--alterations in signal transduction and pharmacogenomics in heart failure
    David S Feldman
    Davis Heart and Lung Research Institute, Division of Cardiology Medicine, Ohio State University, Columbus, OH 43210, USA
    Nat Clin Pract Cardiovasc Med 2:475-83. 2005
    ..In this review, we summarize current insights into beta-adrenergic signal-transduction pathways, the best-described beta-AR polymorphisms, and therapies that target the beta-AR pathway in HF...
  62. doi Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia
    William T Abraham
    Division of Cardiovascular Medicine, The Ohio State University, Columbus, Ohio 43210 1252, USA
    Kidney Int 82:1223-30. 2012
    ..After drug discontinuation, serum sodium concentrations decreased to near-baseline levels within 7 days. Thus, lixivaptan safely and effectively corrects serum sodium concentrations in patients with euvolemic hyponatremia...
  63. doi Development of a method to risk stratify patients with heart failure for 30-day readmission using implantable device diagnostics
    David J Whellan
    Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA
    Am J Cardiol 111:79-84. 2013
    ..In conclusion, device-derived HF diagnostic criteria evaluated 7 days after discharge identified patients at significantly greater risk of a HF event within 30 days after discharge...
  64. ncbi Safety and efficacy of nesiritide for acute decompensated heart failure: recent literature and upcoming trials
    Brian Hiestand
    Department of Emergency Medicine, The Ohio State University, 149 Means Hall, 1654 Upham Drive, Columbus, OH 43210, USA
    Curr Cardiol Rep 9:182-6. 2007
    ..We review the recent evidence regarding the efficacy and safety profile of nesiritide, and discuss upcoming trials designed to address concerns regarding safety and the comparative efficacy of nesiritide...
  65. ncbi Validation and clinical utility of a simple in-home testing tool for sleep-disordered breathing and arrhythmias in heart failure: results of the Sleep Events, Arrhythmias, and Respiratory Analysis in Congestive Heart Failure (SEARCH) study
    William T Abraham
    The Ohio State University Heart Center, Davis Heart and Lung Research Institute, 473 West 12th Avenue, Columbus, OH 43210 1252, USA
    Congest Heart Fail 12:241-7; quiz 248-9. 2006
    ..The device was judged by 80% of patients to be easy or very easy to use, and 74% of patients expressed a preference for the in-home system. Therefore, this system represents a reasonable home testing device in these patients...
  66. ncbi Practical considerations for switching beta-blockers in heart failure patients
    William T Abraham
    Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, Ohio State University Heart Center, Columbus, Ohio, USA
    Rev Cardiovasc Med 5:S36-44. 2004
    ....
  67. ncbi Prevalence of sleep disordered breathing in a heart failure program
    Robin J Trupp
    Davis Heart and Lung Research Institute, Ohio State University, 473 W 12th Avenue, Columbus, OH 43210 1252, USA
    Congest Heart Fail 10:217-20. 2004
    ..Forty-two percent of patients with stable heart failure presenting to a heart failure clinic screened positive for SDB, despite receiving optimal standard of care...
  68. ncbi Cardiology patient page. Cardiac resynchronization therapy: a better and longer life for patients with advanced heart failure
    Srinivas Iyengar
    Division of Cardiovascular Medicine, Ohio State University, Columbus, OH 43210 1252, USA
    Circulation 112:e236-7. 2005
  69. pmc Cardiac effects of continuous and bilevel positive airway pressure for patients with heart failure and obstructive sleep apnea: a pilot study
    Rami N Khayat
    Sleep Heart Program, Ohio State University, Columbus, OH 43210, USA
    Chest 134:1162-8. 2008
    ..The intermediate-term effect of bilevel PAP on left ventricular ejection fraction (LVEF) in patients with stable heart failure and OSA has not been compared to the effect of CPAP...
  70. ncbi Diuretic resistance in heart failure
    Srinivas Iyengar
    The Ohio State University, 473 West 12th Avenue, Rm 110P DHLRI, Columbus, OH 43210 1252, USA
    Curr Heart Fail Rep 3:41-5. 2006
    ..The methods for overcoming this resistance are varied and require a focused approach with emphasis on relieving the congestive symptoms related to HF while attempting to preserve renal function and minimize any untoward systemic effects...
  71. ncbi Highlights of Heart Rhythm 2004, the Annual Scientific Sessions of the Heart Rhythm Society: May 19 to 22, 2004, in San Francisco, California
    Anne B Curtis
    Division of Cardiovascular Medicine, University of Florida, 1600 SW Archer Road, Gainesville, FL 32610, USA
    J Am Coll Cardiol 44:1550-6. 2004
    ....
  72. ncbi Cardiac resynchronization treatment of heart failure
    Ayesha Hasan
    Division of Cardiovascular Medicine, The Ohio State University College of Medicine, Columbus, Ohio 43210 1252, USA
    Annu Rev Med 58:63-74. 2007
    ..With the exponential rise in implants, new issues have emerged, such as optimal device programming, identifying appropriate candidates, and accounting for cases without clinical benefit from CRT...
  73. ncbi Neutral endopeptidase inhibitors and endothelin antagonists: why did the clinical trials not demonstrate beneficial effects?
    Srinivas Iyengar
    Ohio State University, Columbus, OH 43210 1252, USA
    Heart Fail Clin 1:95-102. 2005
  74. ncbi Nonpharmacologic options for the management of heart failure
    Robin J Trupp
    The Ohio State University, Heart and Lung Research Institute, 473 West 12th Avenue, Columbus, OH 43210 1252, USA
    Curr Cardiol Rep 5:243-6. 2003
    ..A variety of nonpharmacologic approaches compliment drug therapy of heart failure, and many have been shown to improve patient quality of life and functional capacity, while reducing morbidity and mortality...
  75. ncbi Anemia in chronic heart failure: can EPO reduce deaths?
    Srinivas Iyengar
    Division of Cardiovascular Medicine The Ohio State University, Columbus 43210 1252, USA
    Cleve Clin J Med 72:1027-32. 2005
    ..Whether treating anemia will improve outcomes in patients with heart failure has yet to be determined, however. The decision to use an agent to treat anemia in heart failure should be made on a case-by-case basis...
  76. doi Relationship of reverse anatomical remodeling and ventricular arrhythmias after cardiac resynchronization
    Steven M Markowitz
    Division of Cardiology, Department of Medicine, Cornell University Medical Center, New York, New York 10021, USA
    J Cardiovasc Electrophysiol 20:293-8. 2009
    ..The purpose of this study is to investigate the relationship of reverse anatomical remodeling to ventricular arrhythmias in CRT patients...
  77. ncbi Higher expectations for management of heart failure: current recommendations
    William T Abraham
    Division of Cardiovascular Medicine, University of Kentucky Medical Center, Lexington, USA
    J Am Board Fam Pract 15:39-49. 2002
    ..Each year 260,000 patients die as a direct or indirect result of the disorder, with annual costs estimated between $21 billion to $40 billion...
  78. ncbi Cardiac resynchronization therapy: a review of clinical trials and criteria for identifying the appropriate patient
    William T Abraham
    Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, Ohio State University, Columbus, OH, USA
    Rev Cardiovasc Med 4:S30-7. 2003
    ..Given these findings, cardiac resynchronization therapy should be routinely considered in eligible NYHA Class III and IV heart failure patients with ventricular dyssynchrony...
  79. ncbi Cardiac resynchronization therapy is important for all patients with congestive heart failure and ventricular dyssynchrony
    William T Abraham
    Department Internal Medicine, Division of Cardiovascular Medicine, and The Davis Heart and Lung Research Institute, Ohio State University, Columbus, USA
    Circulation 114:2692-8; discussion 2698. 2006
  80. ncbi Implications of heart failure drug trials: COMET, CHARM, EPHESUS
    Brian Hiestand
    Department of Emergency Medicine, Ohio State University, Columbus, Ohio, USA
    Rev Cardiovasc Med 6:S4-11. 2005
    ..These trials established that it is feasible to design and execute heart failure studies of sufficient scale to assess improvement in rates of mortality and morbidity...
  81. doi Rationale and design of a randomized clinical trial to assess the safety and efficacy of frequent optimization of cardiac resynchronization therapy: the Frequent Optimization Study Using the QuickOpt Method (FREEDOM) trial
    William T Abraham
    The Ohio State University, Columbus, OH 43017, USA
    Am Heart J 159:944-948.e1. 2010
    ....
  82. ncbi OptiVol fluid status monitoring with an implantable cardiac device: a heart failure management system
    Laura M Yamokoski
    Heart Failure Program, The Ohio State University, OSU Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, 473 W 12th Ave Suite 105, Columbus, OH 43210, USA
    Expert Rev Med Devices 4:775-80. 2007
    ..9% sensitivity. Intrathoracic impedance monitoring is not intended to replace careful frequent clinical evaluation of the heart failure patient, but instead aims to complement traditional heart failure management practices...
  83. doi Reproducibility of peak oxygen uptake and other cardiopulmonary exercise parameters: implications for clinical trials and clinical practice
    Steven J Keteyian
    Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, MI 48202, USA
    Chest 138:950-5. 2010
    ....
  84. doi Cardiac resynchronization therapy may benefit patients with left ventricular ejection fraction >35%: a PROSPECT trial substudy
    Eugene S Chung
    The Christ Hospital and The Ohio Heart and Vascular Center, 2123 Auburn Avenue, Ste 100, Cincinnati, OH, USA
    Eur J Heart Fail 12:581-7. 2010
    ..To evaluate whether patients with LVEF >35% might benefit from CRT, we performed a retrospective analysis of the predictors of response to CRT (PROSPECT) database...
  85. ncbi The evolving challenge of chronic heart failure management: a call for a new curriculum for training heart failure specialists
    Philip B Adamson
    Department of Medicine, Cardiovascular Diseases Section, Department of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, USA
    J Am Coll Cardiol 44:1354-7. 2004
    ..This curriculum outlines a new approach to training interventional HF cardiologists and internal medicine HF specialists to meet the growing demands for specially trained health care providers...
  86. ncbi Pharmacology of carvedilol
    Brian Dulin
    Davis Heart and Lung Research Institute, Columbus, Ohio 43210, USA
    Am J Cardiol 93:3B-6B. 2004
    ..Together, they contribute to the clinical efficacy of carvedilol in a broad spectrum of patient types and may also confer a range of cardioprotective benefits...
  87. ncbi Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study
    Alan S Maisel
    Cardiology 111 A, San Diego VA Medical Center, 3350 La Jolla Village Drive, San Diego, CA 92161, USA
    J Am Coll Cardiol 41:2010-7. 2003
    ..This study examines B-type natriuretic peptide (BNP) levels in patients with systolic versus non-systolic dysfunction presenting with shortness of breath...
  88. ncbi Beta-blocker therapy for heart failure outside the clinical trial setting: findings of a community-based registry
    Joseph A Franciosa
    Mount Sinai School of Medicine and Weill Medical College, Cornell University, New York, NY, USA
    Am Heart J 148:718-26. 2004
    ..beta-Blockers reduce morbidity and mortality rates in heart failure (HF) clinical trials, but it is unknown whether these findings persist in the community setting...
  89. ncbi The effect of diabetes on B-type natriuretic peptide concentrations in patients with acute dyspnea: an analysis from the Breathing Not Properly Multinational Study
    Alan H B Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, Connecticut, USA
    Diabetes Care 27:2398-404. 2004
    ..We determined the effect of diabetes on B-type natriuretic peptide (BNP) concentrations in patients presenting to the emergency department with dyspnea...
  90. ncbi Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents
    Brian D Lowes
    Division of Cardiology and the Cardiovascular Institute, University of Colorado Health Sciences Center, Denver 80262, USA
    N Engl J Med 346:1357-65. 2002
    ..We tested the hypothesis that beta-blocker therapy produces favorable functional effects in dilated cardiomyopathy by altering the expression of myocardial genes that regulate contractility and pathologic hypertrophy...
  91. ncbi Cardiac resynchronization therapy: current state of the art: cost versus benefit
    Angelo Auricchio
    Division of Cardiology, University Hospital, Leipziger Strasse 44, 39120 Magdeburg, Germany
    Circulation 109:300-7. 2004
  92. ncbi Differences in tachyarrhythmia detection and implantable cardioverter defibrillator therapy by primary or secondary prevention indication in cardiac resynchronization therapy patients
    Bruce L Wilkoff
    Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Cardiovasc Electrophysiol 15:1002-9. 2004
    ....
  93. ncbi Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial
    James B Young
    Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    JAMA 289:2685-94. 2003
    ....
  94. ncbi BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy
    Stephen S Gottlieb
    University of Maryland School of Medicine and the D V A Medical Center, Baltimore, MD, USA
    Circulation 105:1348-53. 2002
    ..Adenosine may adversely affect renal function via its effects on renal arterioles and tubuloglomerular feedback, but effects of adenosine blockade in humans receiving furosemide and ACE inhibitors is unknown...
  95. ncbi Does quality of life evidence assist in the selection of patients for resynchronization therapy?
    Peter A McCullough
    Department of Basic Science, Cardiology Section, University of Missouri Kansas City School of Medicine, Truman Medical Center, Kansas City, MO, USA
    Card Electrophysiol Rev 7:71-6. 2003
    ..In conclusion, assessment of quality of life before device implantation is necessary in order to select those individuals who are most likely to benefit from cardiac resynchronization therapy...
  96. ncbi Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure
    Martin G St John Sutton
    Division of Cardiology, University of Pennsylvania Medical Center, Philadelphia, 19104, USA
    Circulation 107:1985-90. 2003
    ..The purpose of the present study was to determine whether improvements in left ventricular (LV) size and function were associated with CRT...
  97. ncbi Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure
    Alan S Maisel
    University of California, San Diego, Veterans Affairs Medical Center, San Diego 92161, USA
    N Engl J Med 347:161-7. 2002
    ..B-type natriuretic peptide is released from the cardiac ventricles in response to increased wall tension...
  98. ncbi Effect of nesiritide versus milrinone in the treatment of acute decompensated heart failure
    Daniel A Lewis
    College of Pharmacy, University of Kentucky Chandler Medical Center, Lexington, USA
    Am J Health Syst Pharm 60:S16-20. 2003
    ..Total cost of therapy was lower in the nesiritide group as compared to those patients treated with milrinone...
  99. ncbi Importance of in-hospital initiation of evidence-based medical therapies for heart failure-a review
    Gregg C Fonarow
    Ahmanson UCLA Cardiomyopathy Center, The David Geffen School of Medicine at UCLA, Los Angeles, California 90095 1679, USA
    Am J Cardiol 94:1155-60. 2004
    ....
  100. doi Worldwide surgical experience with the Paracor HeartNet cardiac restraint device
    Charles T Klodell
    Department of Surgery, Division of Thoracic and Cardiovascular Surgery, University of Florida College of Medicine, Gainesville, Fla 32610, USA
    J Thorac Cardiovasc Surg 135:188-95. 2008
    ..We hypothesize that the Paracor HeartNet device (Paracor Medical, Sunnyvale, Calif), placed through a minithoracotomy in patients with severe dilated cardiomyopathy, improves clinical and functional status...
  101. ncbi Utility of impedance cardiography for the identification of short-term risk of clinical decompensation in stable patients with chronic heart failure
    Milton Packer
    University of Texas Southwestern Medical Center, Dallas, Texas 75390 8822, USA
    J Am Coll Cardiol 47:2245-52. 2006
    ..This study sought to assess the potential utility of impedance cardiography (ICG) in predicting clinical deterioration in ambulatory patients with heart failure (HF)...

Research Grants1

  1. ACTION-A CHF TRIAL INVESTIGATING OUTCOMES OF EXERCISE
    William Abraham; Fiscal Year: 2005
    ..The trial will take place over 5 years with an initial 6 months for planning, training, and implementation; 3 years of enrollment; 1 year of follow-up; and 6 months for close out, analysis, and presentation. ..